1. Home
  2. HOUR vs MDXH Comparison

HOUR vs MDXH Comparison

Compare HOUR & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hour Loop Inc.

HOUR

Hour Loop Inc.

HOLD

Current Price

$1.88

Market Cap

68.3M

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$0.73

Market Cap

68.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
HOUR
MDXH
Founded
2015
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
68.3M
68.7M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
HOUR
MDXH
Price
$1.88
$0.73
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$7.67
AVG Volume (30 Days)
8.2K
15.5M
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
150.00
N/A
EPS
0.05
N/A
Revenue
$142,440,236.00
N/A
Revenue This Year
N/A
$30.78
Revenue Next Year
N/A
$18.31
P/E Ratio
$37.30
N/A
Revenue Growth
3.03
N/A
52 Week Low
$1.67
$0.40
52 Week High
$6.84
$5.33

Technical Indicators

Market Signals
Indicator
HOUR
MDXH
Relative Strength Index (RSI) 50.89 58.35
Support Level $1.74 $0.68
Resistance Level $2.04 $1.13
Average True Range (ATR) 0.08 0.07
MACD 0.00 -0.01
Stochastic Oscillator 63.16 12.12

Price Performance

Historical Comparison
HOUR
MDXH

About HOUR Hour Loop Inc.

Hour Loop Inc is a technology-enabled consumer products company that uses machine learning and data analytics to design, develop, market, and sell products. Hour Loop predominantly operates through online retail channels such as Amazon, Walmart, and Hourloop.com. The company, as an Internet marketplace seller, sells products in multiple categories, including home/garden decor, toys, kitchenware, apparel, and electronics. It has only one segment, which is online retail (e-commerce).

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: